194 related articles for article (PubMed ID: 36157932)
21. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
22. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
Darnell A; Rimola J; Belmonte E; Ripoll E; Garcia-Criado Á; Caparroz C; Díaz-González Á; Vilana R; Reig M; Ayuso C; Bruix J; Forner A
Eur Radiol; 2021 Jul; 31(7):4794-4803. PubMed ID: 33409789
[TBL] [Abstract][Full Text] [Related]
24. Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B.
Moctezuma-Velázquez C; Lewis S; Lee K; Amodeo S; Llovet JM; Schwartz M; Abraldes JG; Villanueva A
JHEP Rep; 2021 Dec; 3(6):100364. PubMed ID: 34712933
[TBL] [Abstract][Full Text] [Related]
25. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
Santillan C; Fowler K; Kono Y; Chernyak V
Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
[TBL] [Abstract][Full Text] [Related]
26. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria.
Ludwig DR; Fraum TJ; Cannella R; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Fleckenstein J; Shetty AS; Borhani AA; Furlan A; Fowler KJ
HPB (Oxford); 2019 Dec; 21(12):1697-1706. PubMed ID: 31262487
[TBL] [Abstract][Full Text] [Related]
27. Cirrhotic liver: What's that nodule? The LI-RADS approach.
Shah A; Tang A; Santillan C; Sirlin C
J Magn Reson Imaging; 2016 Feb; 43(2):281-94. PubMed ID: 25996905
[TBL] [Abstract][Full Text] [Related]
28. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
[TBL] [Abstract][Full Text] [Related]
29. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How?
Cunha GM; Fowler KJ; Abushamat F; Sirlin CB; Kono Y
Clin Liver Dis; 2020 Nov; 24(4):623-636. PubMed ID: 33012449
[TBL] [Abstract][Full Text] [Related]
30. Application of DCE-US using the LI-RADS for patients with liver nodules at high risk for hepatocellular carcinoma: A preliminary study and comparison with visual interpretation.
Qiu S; Ding J; Qin Z; Zhou Y; Zhou H; Wang Y; Zhao L; Jing X
Eur J Radiol; 2022 Oct; 155():110473. PubMed ID: 35988395
[TBL] [Abstract][Full Text] [Related]
31. [Radiologic Diagnosis of Hepatocellular Carcinoma].
Jeong WK
Korean J Gastroenterol; 2021 Nov; 78(5):261-267. PubMed ID: 34824184
[TBL] [Abstract][Full Text] [Related]
32. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
33. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
34. CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners.
Patella F; Pesapane F; Fumarola EM; Emili I; Spairani R; Angileri SA; Tresoldi S; Franceschelli G; Carrafiello G
J Clin Transl Hepatol; 2018 Jun; 6(2):222-236. PubMed ID: 29951368
[TBL] [Abstract][Full Text] [Related]
35. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.
Schellhaas B; Hammon M; Strobel D; Pfeifer L; Kielisch C; Goertz RS; Cavallaro A; Janka R; Neurath MF; Uder M; Seuss H
Eur Radiol; 2018 Oct; 28(10):4254-4264. PubMed ID: 29675659
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Liver Imaging Reporting and Data System on Research Studies of Diagnosing Hepatocellular Carcinoma Using MRI.
Ahn Y; Choi SH; Jang JK; Kim SY; Shim JH; Lee SS; Byun JH
Korean J Radiol; 2022 May; 23(5):529-538. PubMed ID: 35289147
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions.
Wei H; Yang T; Chen J; Duan T; Jiang H; Song B
Liver Int; 2022 Oct; 42(10):2131-2144. PubMed ID: 35808845
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
39. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplant According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma.
Bae JS; Lee DH; Lee SM; Suh KS; Lee KW; Yi NJ; Lee KB; Kim H; Han JK
AJR Am J Roentgenol; 2022 Jul; 219(1):86-96. PubMed ID: 35138137
[No Abstract] [Full Text] [Related]
40. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
